HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Pharmacists Support Providing Nonprescription Naloxone But Training Unavailable

Executive Summary

Two studies revealed a lack of knowledge by pharmacists in Australia about providing naloxone despite being available without a prescription from pharmacists since 2016. Results could be an indication of potential problems if the opioid antagonist is made available nonprescription in US. 

You may also be interested in...



Naloxone OTC Switch Urged By Congressional Coalition Of 30 Democrats And Republicans

In response to highest number of overdose deaths in US history in 2021, 30 members from both chambers of Congress sign letters sent to seven CEOs of naloxone manufacturers.

Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private

Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.

Naloxone In US: ‘Over-Regulated’ And Underused

“A big part of our failure to stop overdose deaths is that the medical and public health establishment cannot reach the populations at greatest risk of overdose,” says overdose prevention researcher Nabarun Dasgupta.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel